Mental Health Medications and GLP-1 Co-Prescribing: What Prescribers Check

The Co-Prescribing Evaluation

When your prescriber evaluates adding a GLP-1 to a medication regimen that includes mental health medications, they're checking three things: pharmacokinetic interactions (does the GLP-1 change how your other medications are absorbed?), pharmacodynamic interactions (do the effects overlap or conflict?), and clinical appropriateness (is GLP-1 therapy safe given your mental health history?).

The good news: GLP-1 medications have a relatively clean interaction profile. They're peptides (or small molecules) that work through specific receptor pathways and generally don't interact with the cytochrome P450 enzyme system that metabolizes most psychiatric medications.

Specific Medication Classes and GLP-1s

SSRIs/SNRIs (sertraline, fluoxetine, venlafaxine, etc.): No significant pharmacokinetic interactions with GLP-1s. However, some SSRIs cause weight changes (gain or loss), which should be factored into your overall weight management plan.

Bupropion (Wellbutrin): No direct interaction. Interestingly, bupropion is a component of Contrave (naltrexone/bupropion), an FDA-approved weight loss medication. Your prescriber should note if you're already on bupropion to avoid inadvertent duplication if naltrexone is ever considered.

Mood stabilizers (lithium, valproate): GLP-1s slow gastric emptying, which can theoretically affect absorption timing for oral medications with narrow therapeutic windows. For lithium specifically, the dehydration risk from GLP-1 GI side effects (nausea, vomiting, diarrhea) can affect lithium levels. Closer monitoring of lithium levels during GLP-1 initiation and titration is prudent.

Antipsychotics (olanzapine, quetiapine, etc.): Several atypical antipsychotics are strongly associated with weight gain. GLP-1s may help counteract this metabolic side effect. Research is emerging on GLP-1s as adjunctive therapy for antipsychotic-induced weight gain.

The Eating Disorder Screen — Why It's Different for Mental Health Patients

Eating disorder screening is important for all GLP-1 patients, but it carries particular weight for patients with existing mental health conditions. Anxiety, depression, PTSD, and other conditions can co-occur with disordered eating patterns that may not meet diagnostic criteria for a formal eating disorder but still represent clinical risk when appetite-suppressing medication is introduced.

Your prescriber should ask about your relationship with food, whether you've ever used restriction or purging behaviors, and whether your mental health treatment has addressed any eating-related concerns. This isn't gatekeeping — it's ensuring that appetite suppression from a GLP-1 doesn't interact negatively with existing mental health vulnerabilities.

Coordination Between Prescribers

If your GLP-1 prescriber and your psychiatric prescriber are different people (which is often the case), ensure both are aware of your full medication list. The most important coordination points: your psychiatrist should know you're starting a GLP-1 (for interaction monitoring and understanding any mood or appetite changes in context), and your GLP-1 prescriber should know your full psychiatric medication list (for absorption timing and dehydration risk management).

Telehealth GLP-1 platforms sometimes don't automatically communicate with your other providers. Take an active role: share your GLP-1 prescription information with your psychiatrist, and share your psychiatric medication list with your GLP-1 prescriber.